Costs and Resource Utilization for Diagnosis and Treatment During the Initial Year in a European Inflammatory Bowel Disease Inception Cohort

An ECCO-EpiCom Study

Johan Burisch, Hillel Vardi, Natalia Pedersen, Marko Brinar, Silvja Cukovic-Cavka, Ioannis Kaimakliotis, Dana Duricova, Martin Bortlik, Olga Shonová, Ida Vind, Søren Avnstrøm, Niels Thorsgaard, Susanne Krabbe, Vibeke Andersen, Jens F Dahlerup, Jens Kjeldsen, Riina Salupere, Jónger Olsen, Kári R Nielsen, Pia Manninen & 31 andre Pekka Collin, Konstantinnos H Katsanos, Epameinondas V Tsianos, Karin Ladefoged, Laszlo Lakatos, Yvonne Bailey, Colm OʼMorain, Doron Schwartz, Guido Lupinacci, Angelo De Padova, Laimas Jonaitis, Limas Kupcinskas, Svetlana Turcan, Louisa Barros, Fernando Magro, Daniela Lazar, Adrian Goldis, Inna Nikulina, Elena Belousova, Alberto Fernandez, Juan R Pineda, Sven Almer, Jonas Halfvarson, Her-Hsin Tsai, Shaji Sebastian, Michael Friger, Dan Greenberg, Peter L Lakatos, Ebbe Langholz, Selwyn Odes, EpiCom Group

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

BACKGROUND:: No direct comparison of health care cost in patients with inflammatory bowel disease across the European continent exists. The aim of this study was to assess the costs of investigations and treatment for diagnostics and during the first year after diagnosis in Europe.

METHODS:: The EpiCom cohort is a prospective population-based inception cohort of unselected inflammatory bowel disease patients from 31 Western and Eastern European centers. Patients were followed every third month from diagnosis, and clinical data regarding treatment and investigations were collected. Costs were calculated in euros (&OV0556;) using the Danish Health Costs Register.

RESULTS:: One thousand three hundred sixty-seven patients were followed, 710 with ulcerative colitis, 509 with Crohn's disease, and 148 with inflammatory bowel disease unclassified. Total expenditure for the cohort was &OV0556;5,408,174 (investigations: &OV0556;2,042,990 [38%], surgery: &OV0556;1,427,648 [26%], biologicals: &OV0556;781,089 [14%], and standard treatment: &OV0556;1,156,520 [22%)]). Mean crude expenditure per patient in Western Europe (Eastern Europe) with Crohn's disease: investigations &OV0556;1803 (&OV0556;2160) (P = 0.44), surgery &OV0556;11,489 (&OV0556;13,973) (P = 0.14), standard treatment &OV0556;1027 (&OV0556;824) (P = 0.51), and biologicals &OV0556;7376 (&OV0556;8307) (P = 0.31). Mean crude expenditure per patient in Western Europe (Eastern Europe) with ulcerative colitis: investigations &OV0556;1189 (&OV0556;1518) (P < 0.01), surgery &OV0556;18,414 (&OV0556;12,395) (P = 0.18), standard treatment &OV0556;896 (&OV0556;798) (P < 0.05), and biologicals &OV0556;5681 (&OV0556;72) (P = 0.51).

CONCLUSIONS:: In this population-based unselected cohort, costs during the first year of disease were mainly incurred by investigative procedures and surgeries. However, biologicals accounted for >15% of costs. Long-term follow-up of the cohort is needed to assess the cost-effectiveness of biological agents.

OriginalsprogEngelsk
TidsskriftInflammatory Bowel Diseases
Vol/bind21
Udgave nummer1
Sider (fra-til)121-131
ISSN1078-0998
DOI
StatusUdgivet - 2015

Fingeraftryk

Inflammatory Bowel Diseases
Eastern Europe
Ulcerative Colitis
Crohn Disease
Cost-Benefit Analysis
Population

Citer dette

Burisch, Johan ; Vardi, Hillel ; Pedersen, Natalia ; Brinar, Marko ; Cukovic-Cavka, Silvja ; Kaimakliotis, Ioannis ; Duricova, Dana ; Bortlik, Martin ; Shonová, Olga ; Vind, Ida ; Avnstrøm, Søren ; Thorsgaard, Niels ; Krabbe, Susanne ; Andersen, Vibeke ; Dahlerup, Jens F ; Kjeldsen, Jens ; Salupere, Riina ; Olsen, Jónger ; Nielsen, Kári R ; Manninen, Pia ; Collin, Pekka ; Katsanos, Konstantinnos H ; Tsianos, Epameinondas V ; Ladefoged, Karin ; Lakatos, Laszlo ; Bailey, Yvonne ; OʼMorain, Colm ; Schwartz, Doron ; Lupinacci, Guido ; De Padova, Angelo ; Jonaitis, Laimas ; Kupcinskas, Limas ; Turcan, Svetlana ; Barros, Louisa ; Magro, Fernando ; Lazar, Daniela ; Goldis, Adrian ; Nikulina, Inna ; Belousova, Elena ; Fernandez, Alberto ; Pineda, Juan R ; Almer, Sven ; Halfvarson, Jonas ; Tsai, Her-Hsin ; Sebastian, Shaji ; Friger, Michael ; Greenberg, Dan ; Lakatos, Peter L ; Langholz, Ebbe ; Odes, Selwyn ; EpiCom Group. / Costs and Resource Utilization for Diagnosis and Treatment During the Initial Year in a European Inflammatory Bowel Disease Inception Cohort : An ECCO-EpiCom Study. I: Inflammatory Bowel Diseases. 2015 ; Bind 21, Nr. 1. s. 121-131.
@article{30fd0a62495341a5921eb4ab07fc66bf,
title = "Costs and Resource Utilization for Diagnosis and Treatment During the Initial Year in a European Inflammatory Bowel Disease Inception Cohort: An ECCO-EpiCom Study",
abstract = "BACKGROUND:: No direct comparison of health care cost in patients with inflammatory bowel disease across the European continent exists. The aim of this study was to assess the costs of investigations and treatment for diagnostics and during the first year after diagnosis in Europe.METHODS:: The EpiCom cohort is a prospective population-based inception cohort of unselected inflammatory bowel disease patients from 31 Western and Eastern European centers. Patients were followed every third month from diagnosis, and clinical data regarding treatment and investigations were collected. Costs were calculated in euros (&OV0556;) using the Danish Health Costs Register.RESULTS:: One thousand three hundred sixty-seven patients were followed, 710 with ulcerative colitis, 509 with Crohn's disease, and 148 with inflammatory bowel disease unclassified. Total expenditure for the cohort was &OV0556;5,408,174 (investigations: &OV0556;2,042,990 [38{\%}], surgery: &OV0556;1,427,648 [26{\%}], biologicals: &OV0556;781,089 [14{\%}], and standard treatment: &OV0556;1,156,520 [22{\%})]). Mean crude expenditure per patient in Western Europe (Eastern Europe) with Crohn's disease: investigations &OV0556;1803 (&OV0556;2160) (P = 0.44), surgery &OV0556;11,489 (&OV0556;13,973) (P = 0.14), standard treatment &OV0556;1027 (&OV0556;824) (P = 0.51), and biologicals &OV0556;7376 (&OV0556;8307) (P = 0.31). Mean crude expenditure per patient in Western Europe (Eastern Europe) with ulcerative colitis: investigations &OV0556;1189 (&OV0556;1518) (P < 0.01), surgery &OV0556;18,414 (&OV0556;12,395) (P = 0.18), standard treatment &OV0556;896 (&OV0556;798) (P < 0.05), and biologicals &OV0556;5681 (&OV0556;72) (P = 0.51).CONCLUSIONS:: In this population-based unselected cohort, costs during the first year of disease were mainly incurred by investigative procedures and surgeries. However, biologicals accounted for >15{\%} of costs. Long-term follow-up of the cohort is needed to assess the cost-effectiveness of biological agents.",
author = "Johan Burisch and Hillel Vardi and Natalia Pedersen and Marko Brinar and Silvja Cukovic-Cavka and Ioannis Kaimakliotis and Dana Duricova and Martin Bortlik and Olga Shonov{\'a} and Ida Vind and S{\o}ren Avnstr{\o}m and Niels Thorsgaard and Susanne Krabbe and Vibeke Andersen and Dahlerup, {Jens F} and Jens Kjeldsen and Riina Salupere and J{\'o}nger Olsen and Nielsen, {K{\'a}ri R} and Pia Manninen and Pekka Collin and Katsanos, {Konstantinnos H} and Tsianos, {Epameinondas V} and Karin Ladefoged and Laszlo Lakatos and Yvonne Bailey and Colm OʼMorain and Doron Schwartz and Guido Lupinacci and {De Padova}, Angelo and Laimas Jonaitis and Limas Kupcinskas and Svetlana Turcan and Louisa Barros and Fernando Magro and Daniela Lazar and Adrian Goldis and Inna Nikulina and Elena Belousova and Alberto Fernandez and Pineda, {Juan R} and Sven Almer and Jonas Halfvarson and Her-Hsin Tsai and Shaji Sebastian and Michael Friger and Dan Greenberg and Lakatos, {Peter L} and Ebbe Langholz and Selwyn Odes and {EpiCom Group}",
year = "2015",
doi = "10.1097/MIB.0000000000000250",
language = "English",
volume = "21",
pages = "121--131",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "Lippincott Williams & Wilkins",
number = "1",

}

Burisch, J, Vardi, H, Pedersen, N, Brinar, M, Cukovic-Cavka, S, Kaimakliotis, I, Duricova, D, Bortlik, M, Shonová, O, Vind, I, Avnstrøm, S, Thorsgaard, N, Krabbe, S, Andersen, V, Dahlerup, JF, Kjeldsen, J, Salupere, R, Olsen, J, Nielsen, KR, Manninen, P, Collin, P, Katsanos, KH, Tsianos, EV, Ladefoged, K, Lakatos, L, Bailey, Y, OʼMorain, C, Schwartz, D, Lupinacci, G, De Padova, A, Jonaitis, L, Kupcinskas, L, Turcan, S, Barros, L, Magro, F, Lazar, D, Goldis, A, Nikulina, I, Belousova, E, Fernandez, A, Pineda, JR, Almer, S, Halfvarson, J, Tsai, H-H, Sebastian, S, Friger, M, Greenberg, D, Lakatos, PL, Langholz, E, Odes, S & EpiCom Group 2015, 'Costs and Resource Utilization for Diagnosis and Treatment During the Initial Year in a European Inflammatory Bowel Disease Inception Cohort: An ECCO-EpiCom Study', Inflammatory Bowel Diseases, bind 21, nr. 1, s. 121-131. https://doi.org/10.1097/MIB.0000000000000250

Costs and Resource Utilization for Diagnosis and Treatment During the Initial Year in a European Inflammatory Bowel Disease Inception Cohort : An ECCO-EpiCom Study. / Burisch, Johan; Vardi, Hillel; Pedersen, Natalia; Brinar, Marko; Cukovic-Cavka, Silvja; Kaimakliotis, Ioannis; Duricova, Dana; Bortlik, Martin; Shonová, Olga; Vind, Ida; Avnstrøm, Søren; Thorsgaard, Niels; Krabbe, Susanne; Andersen, Vibeke; Dahlerup, Jens F; Kjeldsen, Jens; Salupere, Riina; Olsen, Jónger; Nielsen, Kári R; Manninen, Pia; Collin, Pekka; Katsanos, Konstantinnos H; Tsianos, Epameinondas V; Ladefoged, Karin; Lakatos, Laszlo; Bailey, Yvonne; OʼMorain, Colm; Schwartz, Doron; Lupinacci, Guido; De Padova, Angelo; Jonaitis, Laimas; Kupcinskas, Limas; Turcan, Svetlana; Barros, Louisa; Magro, Fernando; Lazar, Daniela; Goldis, Adrian; Nikulina, Inna; Belousova, Elena; Fernandez, Alberto; Pineda, Juan R; Almer, Sven; Halfvarson, Jonas; Tsai, Her-Hsin; Sebastian, Shaji; Friger, Michael; Greenberg, Dan; Lakatos, Peter L; Langholz, Ebbe; Odes, Selwyn; EpiCom Group.

I: Inflammatory Bowel Diseases, Bind 21, Nr. 1, 2015, s. 121-131.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Costs and Resource Utilization for Diagnosis and Treatment During the Initial Year in a European Inflammatory Bowel Disease Inception Cohort

T2 - An ECCO-EpiCom Study

AU - Burisch, Johan

AU - Vardi, Hillel

AU - Pedersen, Natalia

AU - Brinar, Marko

AU - Cukovic-Cavka, Silvja

AU - Kaimakliotis, Ioannis

AU - Duricova, Dana

AU - Bortlik, Martin

AU - Shonová, Olga

AU - Vind, Ida

AU - Avnstrøm, Søren

AU - Thorsgaard, Niels

AU - Krabbe, Susanne

AU - Andersen, Vibeke

AU - Dahlerup, Jens F

AU - Kjeldsen, Jens

AU - Salupere, Riina

AU - Olsen, Jónger

AU - Nielsen, Kári R

AU - Manninen, Pia

AU - Collin, Pekka

AU - Katsanos, Konstantinnos H

AU - Tsianos, Epameinondas V

AU - Ladefoged, Karin

AU - Lakatos, Laszlo

AU - Bailey, Yvonne

AU - OʼMorain, Colm

AU - Schwartz, Doron

AU - Lupinacci, Guido

AU - De Padova, Angelo

AU - Jonaitis, Laimas

AU - Kupcinskas, Limas

AU - Turcan, Svetlana

AU - Barros, Louisa

AU - Magro, Fernando

AU - Lazar, Daniela

AU - Goldis, Adrian

AU - Nikulina, Inna

AU - Belousova, Elena

AU - Fernandez, Alberto

AU - Pineda, Juan R

AU - Almer, Sven

AU - Halfvarson, Jonas

AU - Tsai, Her-Hsin

AU - Sebastian, Shaji

AU - Friger, Michael

AU - Greenberg, Dan

AU - Lakatos, Peter L

AU - Langholz, Ebbe

AU - Odes, Selwyn

AU - EpiCom Group

PY - 2015

Y1 - 2015

N2 - BACKGROUND:: No direct comparison of health care cost in patients with inflammatory bowel disease across the European continent exists. The aim of this study was to assess the costs of investigations and treatment for diagnostics and during the first year after diagnosis in Europe.METHODS:: The EpiCom cohort is a prospective population-based inception cohort of unselected inflammatory bowel disease patients from 31 Western and Eastern European centers. Patients were followed every third month from diagnosis, and clinical data regarding treatment and investigations were collected. Costs were calculated in euros (&OV0556;) using the Danish Health Costs Register.RESULTS:: One thousand three hundred sixty-seven patients were followed, 710 with ulcerative colitis, 509 with Crohn's disease, and 148 with inflammatory bowel disease unclassified. Total expenditure for the cohort was &OV0556;5,408,174 (investigations: &OV0556;2,042,990 [38%], surgery: &OV0556;1,427,648 [26%], biologicals: &OV0556;781,089 [14%], and standard treatment: &OV0556;1,156,520 [22%)]). Mean crude expenditure per patient in Western Europe (Eastern Europe) with Crohn's disease: investigations &OV0556;1803 (&OV0556;2160) (P = 0.44), surgery &OV0556;11,489 (&OV0556;13,973) (P = 0.14), standard treatment &OV0556;1027 (&OV0556;824) (P = 0.51), and biologicals &OV0556;7376 (&OV0556;8307) (P = 0.31). Mean crude expenditure per patient in Western Europe (Eastern Europe) with ulcerative colitis: investigations &OV0556;1189 (&OV0556;1518) (P < 0.01), surgery &OV0556;18,414 (&OV0556;12,395) (P = 0.18), standard treatment &OV0556;896 (&OV0556;798) (P < 0.05), and biologicals &OV0556;5681 (&OV0556;72) (P = 0.51).CONCLUSIONS:: In this population-based unselected cohort, costs during the first year of disease were mainly incurred by investigative procedures and surgeries. However, biologicals accounted for >15% of costs. Long-term follow-up of the cohort is needed to assess the cost-effectiveness of biological agents.

AB - BACKGROUND:: No direct comparison of health care cost in patients with inflammatory bowel disease across the European continent exists. The aim of this study was to assess the costs of investigations and treatment for diagnostics and during the first year after diagnosis in Europe.METHODS:: The EpiCom cohort is a prospective population-based inception cohort of unselected inflammatory bowel disease patients from 31 Western and Eastern European centers. Patients were followed every third month from diagnosis, and clinical data regarding treatment and investigations were collected. Costs were calculated in euros (&OV0556;) using the Danish Health Costs Register.RESULTS:: One thousand three hundred sixty-seven patients were followed, 710 with ulcerative colitis, 509 with Crohn's disease, and 148 with inflammatory bowel disease unclassified. Total expenditure for the cohort was &OV0556;5,408,174 (investigations: &OV0556;2,042,990 [38%], surgery: &OV0556;1,427,648 [26%], biologicals: &OV0556;781,089 [14%], and standard treatment: &OV0556;1,156,520 [22%)]). Mean crude expenditure per patient in Western Europe (Eastern Europe) with Crohn's disease: investigations &OV0556;1803 (&OV0556;2160) (P = 0.44), surgery &OV0556;11,489 (&OV0556;13,973) (P = 0.14), standard treatment &OV0556;1027 (&OV0556;824) (P = 0.51), and biologicals &OV0556;7376 (&OV0556;8307) (P = 0.31). Mean crude expenditure per patient in Western Europe (Eastern Europe) with ulcerative colitis: investigations &OV0556;1189 (&OV0556;1518) (P < 0.01), surgery &OV0556;18,414 (&OV0556;12,395) (P = 0.18), standard treatment &OV0556;896 (&OV0556;798) (P < 0.05), and biologicals &OV0556;5681 (&OV0556;72) (P = 0.51).CONCLUSIONS:: In this population-based unselected cohort, costs during the first year of disease were mainly incurred by investigative procedures and surgeries. However, biologicals accounted for >15% of costs. Long-term follow-up of the cohort is needed to assess the cost-effectiveness of biological agents.

U2 - 10.1097/MIB.0000000000000250

DO - 10.1097/MIB.0000000000000250

M3 - Journal article

VL - 21

SP - 121

EP - 131

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 1

ER -